Nadim Ahmed - Feb 22, 2024 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
President and CEO, Director
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Feb 22, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:00 PM
Previous filing
Dec 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +160K +143.43% $0.00 272K Feb 22, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +320K $0.00 320K Feb 22, 2024 Common Stock 320K $17.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest on an annual basis over four years.
F2 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.